The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data, and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed, organized, and guided by doctors.
Wednesday, June 25th @ 12:00 p.m. Eastern
David Fink will present findings from his recent study, "Cannabis legalization and increasing cannabis use in U.S. Veterans: Novel use of urine toxicology tests in emergency department patients," published in Drug and Alcohol Dependence. This eye-opening session will explore how cannabis legalization is linked to rising cannabis use among U.S. veterans, using innovative analysis of urine toxicology data from emergency departments. Attendees will gain valuable insight into the public health implications of legalization and the unique risks faced by veteran populations.
Speaker: David Fink, PhD, MPH
About the Speaker: David Fink, PhD, MPH, is a substance use and psychiatric epidemiologist whose research spans mental health, substance use, and health policy, unified by a commitment to not only understanding but also addressing the structural, societal, and interpersonal determinants of health across the life course. Dr. Fink’s work focuses on developing and applying rigorous causal inference methods to better understand the causes of addiction and mental illness, with a particular focus on evaluating the impact of federal and state policies and programs, with the goal of informing effective, evidence-based interventions. He earned his MPH in Epidemiology and Biostatistics from San Diego State University and his PhD in Epidemiology from Columbia University, where his research examined the effects of cannabis legalization and prescription drug monitoring programs on drug-related morbidity and mortality. Dr. Fink is currently an Assistant Professor in the Department of Internal Medicine at Yale University. He is funded by the National Institute on Drug Abuse (NIDA) to investigate the effects of expanded telehealth guidelines on buprenorphine prescribing for opioid use disorder.